$306 Million is the total value of Foresite Capital Management III, LLC's 26 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AERI | Buy | Aerie Pharmaceuticals, Inc. | $102,498,000 | +41.6% | 1,950,477 | +22.2% | 33.48% | +20.5% |
| AKAOQ | Buy | Achaogen, Inc. | $27,163,000 | -13.5% | 1,250,000 | +0.4% | 8.87% | -26.4% |
| ALDR | Buy | Alder BioPharmaceuticals, Inc. | $24,929,000 | -26.4% | 2,177,203 | +33.6% | 8.14% | -37.4% |
| BPMC | Buy | Blueprint Medicines Corporation | $23,308,000 | +123.8% | 460,000 | +76.7% | 7.61% | +90.5% |
| WVE | Buy | WAVE Life Sciences Ltd. | $18,676,000 | +0.4% | 1,004,100 | +48.5% | 6.10% | -14.5% |
| IMMU | Buy | Immunomedics, Inc. | $17,138,000 | +1432.9% | 1,940,850 | +1022.7% | 5.60% | +1204.9% |
| EPZM | Buy | Epizyme, Inc. | $12,070,000 | +3.2% | 799,363 | +17.2% | 3.94% | -12.2% |
| TOCA | New | Tocagen, Inc. | $9,059,000 | – | 753,000 | +100.0% | 2.96% | – |
| LOXO | Buy | Loxo Oncology, Inc. | $9,021,000 | +114.4% | 112,500 | +12.5% | 2.95% | +82.5% |
| FGEN | Buy | Fibrogen, Inc. | $8,075,000 | +272.3% | 250,000 | +184.1% | 2.64% | +217.1% |
| VRNA | New | Verona Pharma Plcsponsored ads | $7,152,000 | – | 613,601 | +100.0% | 2.34% | – |
| PACB | New | Pacific Biosciences of California, Inc. | $4,450,000 | – | 1,250,000 | +100.0% | 1.45% | – |
| ARGX | New | argenx SEsponsored adr | $3,744,000 | – | 176,500 | +100.0% | 1.22% | – |
| SGMO | New | Sangamo Therapeutics Inc. | $1,355,000 | – | 154,000 | +100.0% | 0.44% | – |
| INFI | New | Infinity Pharmaceuticals, Inc. | $1,160,000 | – | 738,896 | +100.0% | 0.38% | – |
| BHVN | New | Biohaven Pharmaceutical Holding Company Ltd. | $750,000 | – | 30,000 | +100.0% | 0.24% | – |
| ARDX | New | Ardelyx, Inc. | $191,000 | – | 37,500 | +100.0% | 0.06% | – |
| ABEO | New | Abeona Therapeutics, Inc. | $117,000 | – | 18,334 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.